Becton, Dickinson and Company

- No explicit mention of new fundraising through debt or equity in the disclosed segments. - The company emphasizes disciplined capital allocation with a focus on share repurchases over tuck-in M&A, given the current undervaluation of the stock. - They returned $2.3 billion to shareholders in the quarter, including $2 billion through share repurchases and $0.3 billion in dividends. - They retired $2.1 billion of debt in the quarter and maintain a net leverage target of 2.5x (currently at ~2.9x), highlighting balance sheet discipline. - The company has a strong cash flow generation and prioritizes maintaining a strong balance sheet. - Active M&A pipeline exists but is focused and selective; no plans for large dilutive deals or major capital raises mentioned. - Overall, current strategy favors organic growth, share repurchase, disciplined tuck-in M&A, and balance sheet maintenance rather than new equity or debt fundraising.

- BD is actively investing in focused growth platforms and innovation excellence to drive revenue growth. - The company is expanding its BD Excellence program, applying it beyond operations into commercial and R&D areas to improve efficiency and accelerate timelines. - Network architecture optimization continues, reducing sites to about 50, enabling investment in scaled facilities with informatics and AI capabilities. - Capex includes investments to support new product launches such as the Pyxis Pro (AI- and cloud-enabled) and innovations in pharmacy automation (Parata and Rowa). - BD maintains selective tuck-in M&A to supplement growth but prioritizes share repurchases given current stock valuation. - Capital allocation priorities: return capital to shareholders, invest in focused growth, maintain strong balance sheet discipline. - Strong cash generation supports balanced investment while pursuing operational excellence and technology advancement.

- Biologics now represent ~55% of Pharma Systems revenue, up from 50%, indicating strong growth in a high-growth category. - Multiple key growth platforms delivered double-digit growth in Q2, including biologic drug delivery, Advanced Patient Monitoring (APM), PureWick, and Advanced Tissue Regeneration. - Other areas like oncology, peripheral arterial disease, and Rowa pharmacy automation showed mid- to high single-digit growth. - BD expects revenue growth in the second half of the year to be roughly similar to the first half. - Headwinds from Alaris, vaccines, and China are expected to ease gradually: Alaris headwinds will peak in 2027 and then vanish by 2028. - Focus on innovation pipeline with higher margin, higher growth, and higher WAMGR markets. - Continued targeted tuck-in M&A and strong cash generation will support balanced, focused growth. - Efforts on BD Excellence are accelerating innovation and commercial efficiencies, helping to pull product launch timelines forward by ~10 months.

- BD raised full-year adjusted EPS guidance to $12.52 - $12.72, reflecting confidence in growth amid dynamic environment. - Alaris headwind of 200 basis points expected in FY '27, stabilizing in FY '28 with return to mid-single-digit growth in portfolio. - Innovation pipeline focused on high-growth, higher-margin markets supports margin expansion and revenue growth. - BD expects adjusted operating margins of ~25% inclusive of tariffs, with profitability ahead of expectations. - Continued productivity gains via BD Excellence, including 8% productivity achieved in Q2, expected to improve margins further in latter half of the year. - Revenue growth guidance of low single digits for FY '26 with strong contributions from biologic drug delivery and Advanced Patient Monitoring platforms. - Stable gross margin outlook with tariff headwinds offset by productivity and pricing actions. - Long-term confidence in growth driven by commercial rigor, innovation, and broad portfolio delivering mid-single-digit growth on 90% of business.

- The company highlights strong momentum and competitive traction, particularly with the Pyxis Pro launch, noting the largest competitive funnel in the history of the Alaris business. - Alaris has the largest competitive funnel ever, with about 150 basis points of share gains year-to-date. - Overall, the Alaris competitive funnel is at record levels, reflecting strong demand and execution. - Early customer response to Pyxis Pro, which includes AI-enabled features, has been positive, with 75% of wins being competitive conversions. - Sales teams report best service levels ever, supporting a strong commercial funnel. - The company expresses confidence in continued strong revenue and cash flow growth, with a solid line of sight to performance in the back half of the year. - The commercial focus includes applying BD Excellence principles to improve sales execution and funnel management.